Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Myelodysplastic Syndromes and Acute Myeloid Leukaemia

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.02.09
Views: 13488

Dr Lewis Silverman - Myelodysplastic Syndrome & Myeloproliferative Disease Center, New York

Describes myelodysplastic syndromes, Chronic Myeloid Monosidic Leukemia, MDS patient profiles, MDS progression to AML and azacitidine / vidaza's use for AML Interviewed at ASH 2008. Lewis Silverman is an Associate Professor of Medicine and Director of the Myelodysplastic Syndrome and Myeloproliferative Disease Program, Mount Sinai School of Medicine, in New York City. He served as Principal Investigator of the randomised Phase III trial of Azacitidine vs. Supportive Care which served as the basis for approval of Azacitidine by the FDA for MDS in the United States.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation